Veracyte Revenue and Competitors
Estimated Revenue & Valuation
- Veracyte's estimated annual revenue is currently $143.7M per year.
- Veracyte received $58.9M in venture funding in July 2018.
- Veracyte's estimated revenue per employee is $217,000
- Veracyte's total funding is $681.3M.
Employee Data
- Veracyte has 662 Employees.
- Veracyte grew their employee count by 2% last year.
Veracyte's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer & Chief Medical Officer | Reveal Email/Phone |
2 | Principal Accounting Officer, VP Controller | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Chief Accounting Officer | Reveal Email/Phone |
5 | VP Information Systems | Reveal Email/Phone |
6 | VP Clinical Affairs | Reveal Email/Phone |
7 | Head Sales Operations & Commercial Analytics | Reveal Email/Phone |
8 | VP Marketing & Sales, Pulmonology | Reveal Email/Phone |
9 | SVP & General Manager, Endocrinology | Reveal Email/Phone |
10 | VP, Employment Law & Global HR | Reveal Email/Phone |
Veracyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $434.8M | 1865 | -14% | $2B | $2.7B |
What Is Veracyte?
Veracyte is a pioneering genomic diagnostics company. Our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. We ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. We are giving patients a clearer path forward. Through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. Veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. We are making a difference in the lives of physicians and patients. We are doing something real. .
keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
$681.3M
Total Funding
662
Number of Employees
$143.7M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Veracyte News
Veracyte Insider Transactions Over The Last Year. The Independent Director Jens Holstein made the biggest insider purchase in the last 12 months...
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform...
Analysts expect that Veracyte, Inc. (NASDAQ:VCYT Get Rating) will post earnings per share (EPS) of ($0.23) for the current quarter,...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 22, 2021-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately. This press release fe ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 15, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into 7 of the 10 most common cancers ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $116.5M | 832 | 7% | N/A |
#2 | $748.2M | 1863 | 10% | $2.5B |
#3 | $300M | 2018 | -3% | $15.6M |
#4 | $846.5M | 2458 | N/A | N/A |
#5 | N/A | 4008 | N/A | N/A |
Veracyte Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2010-06-11 | $28.0M | B | Domain Associates | Article |
| 2013-07-01 | $28.0M | C | GE Ventures | Article |
| 2016-03-29 | $45.0M | Undisclosed | Visium Healthcare Partners | Article |
| 2016-11-03 | $30.0M | Undisclosed | Leerink Partners LLC | Article |
| 2018-07-27 | $58.9M | Undisclosed | Leerink Partners | Article |